VPGMarketResearch’s new report is a study of the major business opportunities emerging in the Spanish cancer diagnostics market during the next five years. The report examines trends in the Spanish cancer diagnostics markets, reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

Spain Market Overview

– Five-year test volume and sales projections. – Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers. – Estimated universe of laboratories performing cancer diagnostic testing. – Cancer statistics, etiology and recent developments.

Business Opportunities and Strategic Recommendations

– Specific new product development opportunities with potentially significant market appeal during the next five years. – Design criteria for new products. – Alternative market penetration strategies. – Potential market entry barriers and risks.

Over 200 Current and Emerging Cancer Diagnostic Test

– Biochemical Markers – Oncogenes – Growth Factors – Hormones – Colony Stimulating Factors – Lymphokines – Immunohistochemical Stains, and others.

– ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Supplier Shares, Sales and Volume Forecasts

– Sales and market shares of major cancer diagnostic product suppliers by individual test. – Five-year test volume and sales forecasts for major tumor markers by market segment, including: – Hospitals – Commercial/Private Laboratories

Instrumentation Review

– Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.

Technology Assessment

– Assessment of latest molecular diagnostic methods, biochips/microarrays, biosensors, monoclonal antibodies, immunoassays, chromosome analysis, IT, artificial intelligence, flow cytometry, and other technologies and their potential applications for cancer diagnostic testing. – Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy. – Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Strategies

– Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

– The companies analyzed in the report include:

– Abbott – AdnaGen – Agilent Technologies – Applied Gene Technologies – Arca Biopharma – Beckman Coulter/Danaher – Becton Dickinson – Biomedical Diagnostics – bioMerieux – Bio-Rad – CellSearch – Cepheid – Correlogic Systems/Vermillion – Decode Genetics – Diadexus – Diagnocure – DiaSorin – Eiken Chemical – Elitech Groups – Enterix – Enzo Biochem – Epigenomics – Exact Sciences – Fujirebio – Guided Therapeutics – Hologic/Gen-Probe – Kreatech/Leica – Kyowa Medex – Mackay Life Sciences – Myriad Genetics – OncoLab – Ortho-Clinical Diagnostics – Panacea Pharmaceuticals – Polartechnics – Polymedco – PreMD – Qiagen – Quest Diagnostics – Radient Pharmaceuticals – Roche – Scienion – Sequenom – Siemens Healthcare – Takara Bio – Targeted Diagnostics & Therapeutics – Thermo Fisher – Tosoh – Veridex – Wako Pure Chemicals – Wallac/PE – Zilla

Table of Contents

I. Introduction
II. Major Product Development Opportunities
A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products
III. Design Criteria for Decentralized Testing Products
IV. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
1. Marketing Approaches
2. Product Complexity
3. Customer Preference
4. Established Suppliers
5. Emerging Suppliers
6. Major Types of Distributors
7. Market Segmentation Factor
V. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VI. Worldwide Market and Technology Overview
A. Cancer Statistics and Etiology
1. Breast Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer
B. Major Current And Emerging Cancer Diagnostic Tests
1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembrionic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
- ADA
- B-Protein
- PNP
- 5'-Nucleotidase
27. Oncogenes
- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
- C-myb
- C-myc
- CYP-17
- Erb-B
- HPC1
- N-myc
- P40
- P51
- P53
- PIK3CA
- PTI-1
- Ras
- Reg
- Sis
- Src
28. Polypeptide Growth Factors
- Basic Fibroblast Growth Factor
- Beta-TGF
- Cachectin (TNT)
- Calmodulin
- ECFR
- Nerve Growth Factor (NGF)
- Epidermal Growth Factor (EGF)
- Ornithine Decarboxylase
- Transferrin
- Transforming Growth Factor-Alpha
29. Ectopic Hormones
30. Colony Stimulating Factors
31. Lymphokines
- Alpha-Interferon
- B Cell Growth Factors
- B Cell Growth Factor (BCGF)
- Gamma-Interferon
- Interleukin-1 (IL-1)
- Macrophage Activating Factor
32. Immunohistochemical Stains
33. Emerging Tumor Markers
- N-Acetylglucosamine
- Actin
- Alpha-Actin
- Antineuronal Antibodies
- 7B2
- B72.3
- Bax
- BCD-F9
- BLCA-4
- Blood Group Antigens A,B,H
- CA 50
- CA 72-4/TAG-72
- CA 195
- CA-242
- CA-549
- CAM 26
- CAR-3
- Cathepsin-D
- Chromogranin A and B
- Cluster 1 Antigen
- Cluster-5/5A Antigen
- CTA
- CU18
- DR-70
- DU-PAN-2
- Endometrial Bleeding Associated Factor
- Endostatin
- Epithelial Membrane Antigen
- Feulgen Hydrolysis
- Fibronectin
- FSH
- (1->3)-L-fucosyltransferase
- Gastrin-Releasing Peptide (GRP)
- GDCFP-15
- Glucagon
- Glycoamines
- H23
- Her-2
- Human Carcinoma Antigen
- HPA
- HSP27
- Intermediate Filaments
- Cytokeratins/CK18/Cyfra 21-1
- Desmin
- Gliofibrillary Acid Protein
- Neurofilaments
- Vimentin
- KA 93
- Kinases
- KP16D3
- LAI
- Leukocyte Common Antigen
- Lewis Antigens
- Lysophosphatidic Acid (LPA)
- Ma 695/Ma 552
- MABDF3
- MAG
- ME1
- Minactivin
- MN/CA9
- MSA
- Mucin Cancer Antigen (MCA)
- Multiple Tumor Suppressor 1
- Myosin
- NEA-130
- NMP22
- OA-519
- Opiod Peptides
- P-glycoprotein
- Pancreatic Oncofetal Antigen (POA)
- Placental Lactogen
- PR92
- Proliferative Index, Ki-67
- Px
- RB Inactivation/Deletion
- Ret
- SCCL 175
- Selectin
- Sialic Acid
- Sialyl SSEA-1/SLX
- SN10
- Somatostatin
- TA-90
- TABA
- Tachykinin
- TAG 12
- TPS
- Troponin
- Tubulin
- VCAM
- VEGF
- Villen
C. Instrumentation Review And Market Needs
D. Current and Emerging Technologies
1. Molecular Diagnostics
a. Technology Overview
b. Amplification Methods
c. Sequencing
d. Microarrays/Biochips
2. Monoclonal and Polyclonal Antibodies
3. Immunoassays
a. Technological Principle
b. Radioimmunoassay (RIA)
c. Enzyme Immunoassays (EIA)
- Overview
- ELISA
- Immunofiltration
- Particle-Membrane Capture Immunoassay
- Enzyme Amplification
d. Fluorescent Immunoassays
e. Luminescence
- Chemiluminescence
- Bioluminescence
f. Latex Agglutination
g. Immunoprecipitation
h. Affinity Chromatographu
e. Liposome Flow-Injection Immunoassay
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies
a. CT
b. MRI
c. NMR
d. PET
e. Photonics Spectroscopy
E. Personal Testing
VII. Spain
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers' Sales and Market Shares
VIII. Competitive Profiles
- Abbott
- AdnaGen
- Agilent Technologies
- Applied Gene Technologies
- Arca Biopharma
- Beckman Coulter/Danaher
- Becton Dickinson
- Biomedical Diagnostics
- bioMerieux
- Bio-Rad
- CellSearch
- Cepheid
- Correlogic Systems/Vermillion
- Decode Genetics
- Diadexus
- Diagnocure
- Diasorin
- Eiken Chemical
- Elitech Group
- Epigenomics
Enteri x - Enzo Biochem
- Exact Sciences
- Fujirebio
- Guided Therapeutics
- Hologic/Gen-Probe
Kreate ch/Leica - Kyowa Medex
- Mackay Life Sciences
- Myriad Genetics
- OncoLab
- Ortho-Clinical Diagnostics
- Panacea Pharmaceuticals
- Polartechnics
- Polymedco
- PreMD
- Qiagen
- Quest Diagnostics
- Radient Pharmaceuticals
- Roche
- Scienion
- Sequenom
- Siemens Healthcare
- Takara Bio
- Targeted Diagnostics & Therapeutics
- Thermo Fisher
- Tosoh
- Veridex
- Wako Pure Chemicals
- Wallac/PE
- Zila
IX. Appendix: Major Universities and Research Centers Developing Cancer Diagnostic Technology and Applications

List of Tables

Tumor Marker Classification
Major Companies Developing or Marketing ACTH Tests
Major Companies Developing or Marketing AFP Tests
Major Companies Developing or Marketing Beta-2 Microglobulin Tests
Major Companies Developing or Marketing CA 15-3/27.29 Tests
Major Companies Developing or Marketing CA 19-9 Tests
Major Companies Developing or Marketing CA 125 Tests
Major Companies Developing or Marketing Calcitonin Tests
Major Companies Developing or Marketing CEA Tests
Major Companies Developing or Marketing Estrogen Receptor Tests
Major Companies Developing or Marketing Progesterone Receptor Tests
Major Companies Developing or Marketing Ferritin Tests
Major Companies Developing or Marketing Gastrin Tests
Major Companies Developing or Marketing HCG Tests
Major Companies Developing or Marketing Insulin Tests
Major Companies Developing or Marketing NSE Tests
Major Companies Developing or Marketing Occult Blood Tests
Major Companies Developing or Marketing PAP Smear/HPV Tests
Major Companies Developing or Marketing PAP Tests
Major Companies Developing or Marketing PSA Tests
Major Companies Developing or Marketing Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications In Cancer Diagnosis
Oncogenes Potential Applications In Cancer Diagnosis
Major Companies Developing or Marketing Oncogene Tests
Growth Factors Potential Applications In Cancer Diagnosis
Colony Stimulating Factors Potential Applications in Cancer Diagnosis
Lymphokines Potential Applications In Cancer Diagnosis
Immunohistochemical Stains Potential Applications in Cancer Diagnosis
Executive Summary Table: Spain, Total Tumor Marker Test Volume and Sales Forecast by Market Segment
Spain, Estimated Cancer Death Rates Per 100,000 Population
Spain, Laboratories Performing Tumor Marker Tests by Market Segment
Spain, Hospital Laboratories Performing Tumor Marker Tests by Bed Size
Spain, Commercial/Private Laboratories Performing Tumor Markers by Annual Test Volume
Spain, Total Tumor Marker Test Volume Forecast by Market Segment
Spain, All Market Segment Major Cancer Diagnostic Test Volume Forecast
Spain, Hospital Laboratories Major Cancer Diagnostic Test Volume Forecast by Test
Spain, Commercial/Private Laboratories Major Tumor Marker Test Volume Forecast
Spain, Total Tumor Marker Sales Forecast by Market Segment
Spain, All Market Segments Major Tumor Marker Sales Forecast by Test
Spain, Hospital Laboratories Major Tumor Marker Sales Forecast by Test
Spain, Commercial/Private Laboratories Major Tumor Marker Sales Forecast by Test
Spain, AFP Test Volume and Diagnostics Sales Forecast by Market Segment
Spain, Beta-2 Microglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
Spain, CA 15-3 Test Volume and Diagnostics Sales Forecast by Market Segment
Spain, CA 19-9 Test Volume and Diagnostics Sales Forecast by Market Segment
Spain, CA-125 Test Volume and Diagnostics Sales Forecast by Market Segment
Spain, Calcitonin Test Volume and Diagnostics Sales Forecast by Market Segment
Spain, CEA Test Volume and Diagnostics Sales Forecast by Market Segment
Spain, Colon-Specific Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
Spain, Estrogen Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
Spain, Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment
Spain, Gastrin Test Volume and Diagnostics Sales Forecast by Market Segment
Spain, HCG Test Volume and Diagnostics Sales Forecast by Market Segment
Spain, Insulin Test Volume and Diagnostics Sales Forecast by Market Segment
Spain, Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast by Market Segment
Spain, NSE Test Volume and Diagnostics Sales Forecast by Market Segment
Spain, Occult Blood Test Volume and Diagnostics Sales Forecast by Market Segment
Spain, Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment
Spain, Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
Spain, PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment
Spain, Parathyroid Hormone Test Volume and Diagnostics Sales Forecast by Market Segment
Spain, Progesterone Receptor Test Volume and Diagnostics Sales Forecast By Market Segment
Spain, PAP Test Volume and Diagnostics Sales Forecast by Market Segment
Spain, PSA Test Volume and Diagnostics Sales Forecast by Market Segment
Spain, S-100 Protein Test Volume and Diagnostics Sales Forecast by Market Segment
Spain, Serotonin Test Volume and Diagnostics Sales Forecast by Market Segment
Spain, Sialic Acid Test Volume and Diagnostics Sales Forecast by Market Segment
Spain, Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast By Market Segment
Spain, TDT Test Volume and Diagnostics Sales Forecast by Market Segment
Spain, Thymidine Kinase Test Volume and Diagnostics Sales Forecast by Market Segment
Spain, Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
Spain, TPA Test Volume and Diagnostics Sales Forecast by Market Segment
Spain, Total Tumor Marker Sales by Major Suppliers
Spain, AFP Testing Market Diagnostics Sales By Major Supplier
Spain, CA 15-3/27.29 Testing Market Diagnostics Sales by Major Supplier
Spain, 19-9 Testing Market Diagnostics Sales By Major Supplier
Spain, CA 125 Testing Market Diagnostics Sales By Major Supplier
Spain, CEA Testing Market Diagnostics Sales By Major Supplier
Spain, PSA Testing Market Diagnostics Sales By Major Supplier